This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Busam, K. J. Articles by Rivers, J. Search for Related Content PubMed PubMed Citation Articles by Busam, K. J. Articles by Rivers, J.

American Journal of Pathology, Vol 147, 1049-1056, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Tumor vascularity is not a prognostic factor for malignant melanoma of the skin

KJ Busam, M Berwick, K Blessing, K Fandrey, S Kang, T Karaoli, J Fine, AJ Cochran, WL White and J Rivers
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Tumor vascularity has been proposed as a prognostic indicator for a number of solid tumors. Although a correlation between microvessel number and metastatic behavior has also been suggested for cutaneous melanoma, the small number of cases studied to date allows one to draw only preliminary conclusions. In this study, we have assessed tumor vascularity in cutaneous melanoma by comparing 60 cases of metastasizing and non-metastasizing tumors matched for tumor thickness, age, sex, and anatomic site. Ulex europaeus agglutinin I appeared to be the most suitable vascular marker for this study. Our results indicate that there was no statistically significant difference between the two groups with regard to tumor vascularity. Even after identifying 15 cases of thin ( < 1.0 mm thick) melanoma, there was no significant difference in the number of microvessels between metastasizing and non- metastasizing tumors. Comparison of patterns of vascular microarchitecture also failed to discriminate between the two groups. Thus, our results indicate that tumor vascularity may not be an independent prognostic factor for cutaneous melanoma.

This article has been cited by other articles:

				D Sahni, A Robson, G Orchard, R Szydlo, A V Evans, and R Russell-Jones The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status J. Clin. Pathol., July 1, 2005; 58(7): 715 - 721. [Abstract] [Full Text] [PDF]

				S. S. Dadras, T. Paul, J. Bertoncini, L. F. Brown, A. Muzikansky, D. G. Jackson, U. Ellwanger, C. Garbe, M. C. Mihm, and M. Detmar Tumor Lymphangiogenesis: A Novel Prognostic Indicator for Cutaneous Melanoma Metastasis and Survival Am. J. Pathol., June 1, 2003; 162(6): 1951 - 1960. [Abstract] [Full Text] [PDF]

				C. Cohen, A. Zavala-Pompa, J. H. Sequeira, M. Shoji, D. G. Sexton, G. Cotsonis, F. Cerimele, B. Govindarajan, N. Macaron, and J. L. Arbiser Mitogen-actived Protein Kinase Activation Is an Early Event in Melanoma Progression Clin. Cancer Res., December 1, 2002; 8(12): 3728 - 3733. [Abstract] [Full Text] [PDF]

				L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]

				R. Clarijs, I. Otte-Holler, D. J. Ruiter, and R. M. W. de Waal Presence of a Fluid-Conducting Meshwork in Xenografted Cutaneous and Primary Human Uveal Melanoma Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 912 - 918. [Abstract] [Full Text] [PDF]

				M. Kashani-Sabet, R. W. Sagebiel, C. M.M. Ferreira, M. Nosrati, and J. R. Miller III Tumor Vascularity in the Prognostic Assessment of Primary Cutaneous Melanoma J. Clin. Oncol., April 1, 2002; 20(7): 1826 - 1831. [Abstract] [Full Text] [PDF]

				J. L. Yu, J. W. Rak, G. Klement, and R. S. Kerbel Vascular Endothelial Growth Factor Isoform Expression as a Determinant of Blood Vessel Patterning in Human Melanoma Xenografts Cancer Res., March 1, 2002; 62(6): 1838 - 1846. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Importance of Vascular Phenotype by Basic Fibroblast Growth Factor, and Influence of the Angiogenic Factors Basic Fibroblast Growth Factor/Fibroblast Growth Factor Receptor-1 and Ephrin-A1/EphA2 on Melanoma Progression Am. J. Pathol., March 1, 2002; 160(3): 1009 - 1019. [Abstract] [Full Text] [PDF]

				M. Kashani-Sabet, R. W. Sagebiel, C. M. M. Ferreira, M. Nosrati, and J. R. Miller III Vascular Involvement in the Prognosis of Primary Cutaneous Melanoma Arch Dermatol, September 1, 2001; 137(9): 1169 - 1173. [Abstract] [Full Text] [PDF]

				O. Straume and L. A. Akslen Expresson of Vascular Endothelial Growth Factor, Its Receptors (FLT-1, KDR) and TSP-1 Related to Microvessel Density and Patient Outcome in Vertical Growth Phase Melanomas Am. J. Pathol., July 1, 2001; 159(1): 223 - 235. [Abstract] [Full Text] [PDF]

				R. Clarijs, L. Schalkwijk, D. J. Ruiter, and R. M. W. de Waal Lack of Lymphangiogenesis Despite Coexpression of VEGF-C and Its Receptor Flt-4 in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1422 - 1428. [Abstract] [Full Text]

				T. E. Konopka, J. E. Barker, T. L. Bamford, E. Guida, R. L. Anderson, and A. G. Stewart Nitric Oxide Synthase II Gene Disruption: Implications for Tumor Growth and Vascular Endothelial Growth Factor Production Cancer Res., April 1, 2001; 61(7): 3182 - 3187. [Abstract] [Full Text]

				R. Folberg, M. J. C. Hendrix, and A. J. Maniotis Vasculogenic Mimicry and Tumor Angiogenesis Am. J. Pathol., February 1, 2000; 156(2): 361 - 381. [Abstract] [Full Text] [PDF]